Infliximab biosimilars are safe, effective, and cheap, UK audit showsBMJ 2016; 354 doi: http://dx.doi.org/10.1136/bmj.i5084 (Published 22 September 2016) Cite this as: BMJ 2016;354:i5084
- Caroline White
Infliximab “biosimilars”—biological therapies engineered to work in the same way as the monoclonal antibody drug infliximab (marketed as Remicade)—are safe and effective and could halve the cost of inflammatory bowel disease (IBD) treatment, a report by the Royal College of Physicians has found.1
Use of these drugs could cut the cost of an annual course of treatment from around £10 000 (€11 700: $13 000) to around £5000, the authors said.
Given their reduced cost, clinicians should use biosimilars as first line treatment for appropriate patients with active IBD and should consider switching those currently being treated with Remicade, said the report.
Only a fifth of patients were receiving infliximab biosimilars (Inflectra and Remsima), the audit found, prompting the authors to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial